Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score.
Pérez de Llano L, Dávila I, Martínez-Moragón E, Domínguez-Ortega J, Almonacid C, Colás C, García-Rivero JL, Carmona L, García de Yébenes MJ, Cosío BG; FEOS Study Group. Pérez de Llano L, et al. Among authors: almonacid c. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2725-2731. doi: 10.1016/j.jaip.2021.01.033. Epub 2021 Feb 4. J Allergy Clin Immunol Pract. 2021. PMID: 33549843
Knowledge of their own allergic sensitizations in asthmatic patients and its impact on the level of asthma control.
Roger A, Vázquez R, Almonacid C, Padilla A, Serrano J, García-Salmones M, Molina F, Pinedo C, Torrejón M, Picado C, López-Viña A, Plaza V; Grupo Emergente Asma. Área Asma de SEPAR. Roger A, et al. Among authors: almonacid c. Arch Bronconeumol. 2013 Jul;49(7):289-96. doi: 10.1016/j.arbres.2013.02.004. Epub 2013 Apr 6. Arch Bronconeumol. 2013. PMID: 23566766 English, Spanish.
A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future.
Pérez de Llano L, Miravitlles M, Golpe R, Alvarez-Gutiérrez FJ, Cisneros C, Almonacid C, Martinez-Moragon E, Gonzalez-Barcala FJ, Ramos-Barbón D, Plaza V, Lopez-Campos JL, de-Torres JP, Casanova C, Garcia Rivero JL, Rodriguez Hermosa J, Calle Rubio M, Soler-Cataluña JJ, Cosio BG. Pérez de Llano L, et al. Among authors: almonacid c. Int J Chron Obstruct Pulmon Dis. 2020 Sep 4;15:2091-2100. doi: 10.2147/COPD.S263430. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32943862 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33229047
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study.
Toledo-Pons N, van Boven JFM, Muncunill J, Millán A, Román-Rodríguez M, López-Andrade B, Almonacid C, Álvarez DV, Kocks JWH, Cosío BG. Toledo-Pons N, et al. Among authors: almonacid c. Ann Am Thorac Soc. 2022 Mar;19(3):407-414. doi: 10.1513/AnnalsATS.202103-409OC. Ann Am Thorac Soc. 2022. PMID: 34534050
[Teleconsultation in the follow-up of the asthma patient. Lessons after COVID-19].
Almonacid C, Blanco-Aparicio M, Domínguez-Ortega J, Giner J, Molina J, Plaza V; en representación del grupo de trabajo COMETA. Almonacid C, et al. Arch Bronconeumol. 2021 Jan;57:13-14. doi: 10.1016/j.arbres.2020.10.005. Epub 2020 Oct 22. Arch Bronconeumol. 2021. PMID: 34629633 Free PMC article. Spanish. No abstract available.
30 results